Just ahead of the expected release of clinical practice guidelines on Familial Hypercholesterolaemia (FH) by the influential National Institute for Clinical Excellence (NICE), Tepnel Life Sciences PLC launched a DNA test for the early detection of FH, a genetic condition that predisposes individuals to high blood cholesterol levels and increased risk of cardiovascular disease.
If you enjoy this content, please share it with a colleague
New DNA Test Detects Familial Hypercholesterolaemia
Related Content
August 5, 2019 — A West Virginia-based rural medical outreach event showcased the use of point-of-care technology in an ...
July 26, 2017 — Siemens Healthineers has entered into a definitive agreement to acquire Epocal Inc., a subsidiary of ...
July 17, 2017 — Despite issues with point-of-care INR testing company Alere Inc., Abbott announced this week it is once ...
Point-of-care (POC) coagulation analyzers that measure prothrombin time/international normalized ratio (PT/INR) on ...
January 27, 2017 — HyperMed Imaging Inc. announced that it has received clearance from the U.S. Food and Drug ...
Point of care testing devices are gaining widespread approval for prompt medical diagnoses, especially in cardiology and ...
December 7, 2016 — Abbott has filed a complaint to terminate its proposed acquisition of Alere based on the substantial ...
November 10, 2016 — Siemens Healthineers announced U.S. Food and Drug Administration (FDA) 510(k) clearance for a hand ...
February 3, 2016 — Abbott and Alere Inc. announced a definitive agreement for Abbott to acquire Alere. Under the terms ...
December 22, 2015 — Trinity Biotech plc announced submission of its Meritas Point of Care Analyzer and Meritas cardiac ...